专利检索 ap:("Theravance, Inc.") AND inv:"OGAWA, Gavin" 第 1 页

1.

发明公开
ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2- [4- (BI PHENYL - 4 - YL) - 1H - IMIDAZO - 2 - YL]PYRROLIDINE - 1 - CARBONLYMETHYL} AMINE 有权
标题翻译：棒状肝炎C-病毒缝边与片断{2- [4-（联苯-4-基）-1H-咪唑-2-基]吡咯烷-1- AMIN CARBONLYMETHYL-

公开(公告)号：EP2773634A1

公开(公告)日：2014-09-10

申请号：EP12783835.7

申请日：2012-11-02

申请人： Theravance, Inc.

发明人： LONG, Daniel D. , MCKINNELL, Robert Murray , JIANG, Lan , LOO, Mandy , LEPACK, Kassandra , VAN ORDEN, Lori Jean , OGAWA, Gavin , HUANG, Xiaojun , ZHANG, Weijiang

IPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D491/113 , A61K31/4439 , A61K31/4433 , A61P31/12 , A61P31/14

CPC分类号： A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D491/113

摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

2.

发明公开
NOVEL INHIBITORS OF HEPATITIS C VIRUS 有权
标题翻译：新的丙型肝炎病毒抑制剂

公开(公告)号：EP2635571A1

公开(公告)日：2013-09-11

申请号：EP11784875.4

申请日：2011-11-03

申请人： Theravance, Inc.

发明人： MCKINNELL, Robert Murray , LONG, Daniel D. , VAN ORDEN, Lori Jean , JIANG, Lan , LOO, Mandy , SAITO, Daisuke Roland , ZIPFEL, Sheila , STANGELAND, Eric L. , LEPACK, Kassandra , OGAWA, Gavin , HUANG, Xiaojun , ZHANG, Weijiang

IPC分类号： C07D403/14 , A61K31/4025 , A61K31/12

CPC分类号： C07D401/14 , A61K31/496 , A61K45/06 , C07D403/14

摘要： The invention provides compounds of formula (I) wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.